RANKL-OPG and RAGE modulation in vascular calcification and diabetes: novel targets for therapy

Agbor Ndip1, Fiona L Wilkinson, Edward B Jude

  • 1Department of Medicine and Diabetes, Manchester Royal Infirmary, Manchester, UK, agbor.ako@manchester.ac.uk.

Diabetologia
|August 13, 2014
PubMed

Insights

Type 2 diabetes accelerates vascular aging and calcification, increasing cardiovascular risk. Targeting pathways like RANKL-RANK-OPG and RAGE shows promise for new therapies beyond glucose control.

Area of Science:

  • Cardiovascular Science
  • Endocrinology
  • Vascular Biology

Background:

  • Type 2 diabetes (T2D) is linked to heightened cardiovascular disease (CVD) risk and premature vascular aging.
  • Vascular calcification, a key feature of atherosclerosis, independently predicts CVD morbidity and mortality in T2D patients.
  • Conventional glucose-lowering therapies have limited success in improving macrovascular outcomes in T2D.

Purpose of the Study:

  • To explore emerging regulatory pathways involved in vascular calcification in T2D.
  • To identify novel biomarkers and therapeutic targets for T2D-associated vascular complications.
  • To evaluate the potential of targeting specific signaling pathways for improved cardiovascular outcomes.

Main Methods:

  • Review of current clinical and basic science evidence on vascular calcification in T2D.
  • Analysis of the roles of the receptor activator of nuclear factor kappa B (RANK), RANK ligand (RANKL), and osteoprotegerin (OPG) pathways.
  • Investigation of the receptor for advanced glycation end products (RAGE) signaling and inflammatory markers.

Main Results:

  • The RANK-RANKL-OPG system is identified as a key regulatory pathway in diabetic vascular calcification.
  • Glycation and inflammation levels serve as important biomarkers for vascular calcification in diabetes.
  • Targeting RANKL and RAGE signaling pathways presents potential therapeutic strategies.

Conclusions:

  • Modulating RANKL-RANK-OPG signaling, RAGE signaling, and the inflammatory environment may alter the course of cardiovascular complications in T2D.
  • Novel therapeutic strategies targeting these pathways could offer benefits beyond conventional glucose management.
  • Further research is essential to elucidate precise mechanisms and translate these findings into clinical benefits for patients.

Related Concept Videos

Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
48
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration...
25
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.8K